Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Der Urologe. Ausg. A|July 12, 2015
[Radionuclide therapy and diagnostics in urology]W P Fendler, V Wenter, C G Stief, et al.
European Journal of Nuclear Medicine and Molecular Imaging|March 1, 2018
Biological tumour volumes of gliomas in early and standard 20-40 min <sup>18</sup>F-FET PET images differ according to IDH mutation statusM Unterrainer, I Winkelmann, B Suchorska, et al.
European Journal of Nuclear Medicine and Molecular Imaging|March 16, 2018
Correction to: Biological tumour volumes of gliomas in early and standard 20-40 min <sup>18</sup>F-FET PET images differ according to IDH mutation statusM Unterrainer, I Winkelmann, B Suchorska, et al.
BMC Cancer|August 10, 2019
Salvage PRRT with <sup>177</sup>Lu-DOTA-octreotate in extensively pretreated patients with metastatic neuroendocrine tumor (NET): dosimetry, toxicity, efficacy, and survivalS Rudisile, A Gosewisch, V Wenter, et al.
European Journal of Nuclear Medicine and Molecular Imaging|August 20, 2017
TSPO PET for glioma imaging using the novel ligand <sup>18</sup>F-GE-180: first results in patients with glioblastomaNathalie L Albert, M Unterrainer, D F Fleischmann, et al.
European Journal of Nuclear Medicine and Molecular Imaging|September 24, 2018
Comparison of <sup>18</sup>F-GE-180 and dynamic <sup>18</sup>F-FET PET in high grade glioma: a double-tracer pilot studyMarcus Unterrainer, D F Fleischmann, C Diekmann, et al.
European Journal of Nuclear Medicine and Molecular Imaging|September 6, 2019
TSPO PET, tumour grading and molecular genetics in histologically verified glioma: a correlative <sup>18</sup>F-GE-180 PET studyM Unterrainer, D F Fleischmann, F Vettermann, et al.
Pageof 1